黄卫娟,何秀云,陈海燕
HUANG Weijuan,HE Xiuyun,CHEN Haiyan

• 1:东莞市第五人民医院

摘要(Abstract)：

目的调查既往植入冠脉支架的非瓣膜性心房颤动住院患者,总结临床抗栓策略选择的现状及相关影响因素。方法回顾分析2008~2013年在本院住院的325例植入冠脉支架的非瓣膜病心房颤动患者,分析其抗栓药物的选择及原因。结果临床上选择阿司匹林联合氯吡格雷较多占52.3%,选华法林抗栓的较少,仅占37.2%;住院科室和消化道病史对抗栓方案的选择有影响,而CHADS2评分和植入支架类型影响不大。结论在既往植入冠脉支架的非瓣膜病心房颤动的患者中,总体使用华法林抗栓占比重较小,在非心内科住院的患者中比重更小;对于有胃炎病史的患者,临床医生很少加用阿司匹林抗栓,CHADS2评分和植入支架类型对临床抗栓策略的选择影响不大。
OBJECTIVE To investigate and summarize the current clinical features of antithrombotic strategies and the potential factors which impact on the decision of antithrombotic treatment in patients with non-valvular atrial fibrillation after coronary artery stent implantation. METHODS The clinical data of 325 inpatients diagnosed with non-valvular atrial fibrillation after coronary artery stent implantation from 2008 to 2013 in the hospital were retrospectively analyzed. RESULTS 52. 3% of the patients were treated by aspirin combined with clopidogrel,only 37. 2% were treated by warfarin. The antithrombotic strategy selection was influenced by the hospital department which the patients were admitted to and the previous history of digestive disease. However,CHADS2 scores and the types of stents had little influence on the selection of antithrombotic treatment. CONCLUSION The proportion of warfarin therapy was low in non-cardiovascular departments in the patients with non-valvular atrial fibrillation after coronary artery stent implantation. Aspirin was rarely added in the antithrombotic treatment in patients with known history of digestive disease.

关键词(KeyWords)： 心房颤动;预防支架;抗血栓药
atrial fibrillation;prevention stents;antithrombotic

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 黄卫娟,何秀云,陈海燕
HUANG Weijuan,HE Xiuyun,CHEN Haiyan

参考文献(References)：

• [1]胡大一,杨进刚.心房颤动的现代观点[J].中国循环杂志,2004,19:323-324.
• [2]Glazer L,Dublin S,Smith N,et al.Risk factor for stroke and efficacy of antithrombotie therapy in atrial fibrillation-Analysis of pooled data from five randomized controlled trials[J].A I M,1994,154:1449-1457.
• [3]黄从新,马长生,吴书林,等.心房颤动:目前的认识和治疗建议(二)[J].中华心律失常学杂志,2012,03:167-197.
• [4]Steinhubl SR,Berger PB,Mann JT,et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J].The Journal of The American Medical Association,2002,21:324-341.
• [5]金钦阳,屈百鸣.房颤合并冠心病抗栓治疗的新认识——基于2010ESC心房颤动治疗指南[S].心脑血管病防治,2011,11:12-16.
• [6]胡大一,张鹤萍,孙艺红,等.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,04:295-298.
• [7]Fuster V,Ryden L,Aannom D,et al.ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation[J].JACC,2006,27:1979-2030.
• [8]陈纪林,郭远林.冠心病合并心房颤动患者抗凝治疗方案的选择[J].中国循环杂,2011,04:64-68.
• [9]Li-Saw-Hee FL,Blann AD,Lip GY.Effects of fixed low-dose warfarin aspirin-warfarin combination therapy and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation[J].Stroke,2000,31:828-833.